CancerTYPE ID test diagnostic data

bioMerieux's bioTheranostics Inc. subsidiary reported data from 122 metastatic tumor samples of unknown primary origin showing that the CancerTYPE ID test had a significantly greater overall accuracy for determining primary tumor site compared with immunohistochemistry (78% vs. 68%, p=0.019). Additionally, CancerTYPE ID showed higher sensitivities for correctly determining if lung cancer (75% vs. 67%), urinary bladder cancer (75% vs. 42%) and breast cancer (73% vs. 55%) samples were of a primary tumor site compared to immunohistochemistry. The study was conducted in collaboration with the City of Hope National Medical Center. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...